v3.25.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Current assets:    
Cash $ 3,727 $ 142
Accounts receivable 109 109
Net investment in leases, short term 13
Prepaid expenses and vendor deposits 150 80
Total current assets 3,986 344
Property and equipment, net 68 85
Right-to-use assets, net 55 96
Other assets:    
Net investment in leases, long term 4
Patents, net 265 269
Other assets 44 44
Total assets 4,418 842
Current liabilities:    
Accounts payable and accrued expenses, including $0 and $19 to related parties as of March 31, 2025 and December 31, 2024, respectively 1,507 2,052
Dividends payable 112 110
Lease liability, short term 60 102
Total current liabilities 1,679 2,264
Total liabilities 1,679 2,264
Commitments and contingencies (Note 11)
Series C 9% Convertible Preferred Stock, $0.001 par value, $1,000 stated value, authorized 4,200 shares, 105 shares issued and outstanding; liquidation preference of $105 as of March 31, 2025 and December 31, 2024 105 105
Equity (Deficit)    
Preferred stock, $0.001 par value, authorized 1,000,000 shares, designated 200 shares of Series A, 600 shares of Series B, 4,200 shares of Series C, 1,400 shares of Series D, 1,000 shares of Series E, 200,000 shares of Series F Preferred Stock. 105 shares of Series C outstanding as of March 31, 2025 and December 31, 2024 (see above)
Common stock, $0.001 par value, authorized 200,000,000 shares, 24,248,315 and 17,239,096 issued and outstanding as of March 31, 2025 and December 31, 2024, respectively 24 17
Additional paid-in-capital 260,738 253,784
Accumulated deficit (258,157) (255,345)
Total stockholders’ equity (deficit) attributable to BioSig Technologies, Inc. 2,605 (1,544)
Non-controlling interest 29 17
Total equity (deficit) 2,634 (1,527)
Total liabilities and equity (deficit) $ 4,418 $ 842

Source